Funded Biomarker Testing
39 items
Reflex testing for all newly diagnosed paragangliomas (to inform need for germline testing)
Funded Biomarker Disease Site: Multiple Disease Sites
Biomarker: SDHB
Testing Method:Immunohistochemistry (IHC)
Testing Site: London Health Sciences Centre, Mount Sinai Hospital, Sunnybrook Health Sciences Centre, University Health Network, William Osler Health System
Reflex testing for the diagnosis of serous tumours (epithelial ovarian, fallopian tube, peritoneal cancers) when needed to establish histologic subtype.
Funded Biomarker Disease Site: Ovary
Biomarker: p53, WT1
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North Bay Regional Health Centre, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System
Reflex testing on all metastatic thyroid cancer, including sporadic medullary and radio-iodine refractory well differentiated thyroid cancer.
Funded Biomarker Disease Site: Thyroid
Biomarker: BRAF, HRAS, NRAS, NTRK3, PPARG, RET, KRAS
Testing Method:Panel
Testing Site: Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System
Reflex testing on all newly diagnosed breast cancers.
Funded Biomarker Disease Site: Breast
Biomarker: HER2, ER, PR
Testing Method:Immunohistochemistry (IHC)
Testing Site: Grand River Hospital, Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, Lakeridge Health, London Health Sciences Centre, Mount Sinai Hospital, North York General Hospital, Royal Victoria Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Thunder Bay Regional Health Sciences Centre, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System, Windsor Regional Hospital
Reflex testing on all newly diagnosed breast cancers.
Funded Biomarker Disease Site: Breast
Biomarker: HER2
Testing Method:In Situ Hybridization (ISH)
Testing Site: Grand River Hospital, Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, Lakeridge Health, London Health Sciences Centre, Mount Sinai Hospital, North York General Hospital, Royal Victoria Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Thunder Bay Regional Health Sciences Centre, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System, Windsor Regional Hospital
Reflex testing on all newly diagnosed ductal carcinoma in situ (DCIS).
Funded Biomarker Disease Site: Breast
Biomarker: ER
Testing Method:Immunohistochemistry (IHC)
Testing Site: Grand River Hospital, Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, Lakeridge Health, London Health Sciences Centre, Mount Sinai Hospital, North York General Hospital, Royal Victoria Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Thunder Bay Regional Health Sciences Centre, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System, Windsor Regional Hospital
Reflex testing on cases of adult patients with persistent, recurrent, or metastatic cervical cancer when treatment is being considered
Funded Biomarker Disease Site: Cervix
Biomarker: PD-L1 (CPS ≥1)
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, London Health Sciences Centre, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System
Reflex testing on newly diagnosed cases advanced*/metastatic colorectal or small bowel carcinoma.
Funded Biomarker Disease Site: Colorectal, Small Bowel
Biomarker: BRAF, KRAS, NRAS, PIK3CA
Optional for 21/22: PTEN
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System
Reflex testing on newly diagnosed cases of advanced*/metastatic melanoma.
Funded Biomarker Disease Site: Melanoma
Biomarker: BRAF, KIT, NRAS
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System
Reflex testing on newly diagnosed cases of NSCLC (adenocarcinoma/non-squamous).
Funded Biomarker Disease Site: Lung
Biomarker: PD-L1, ALK, EGFR, ROS1, BRAF, MET (Met Skipping), RET, FGFR1, HER2 (ERBB2), KRAS, PIK3CA, NTRK1, NTRK2, NTRK3
Optional for 22/23: NRG1, TP53, STK11, KEAP1
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System
Reflex testing on newly diagnosed cases of NSCLC (squamous).
Funded Biomarker Disease Site: Lung
Biomarker: PD-L1
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System
Reflex testing on newly diagnosed epithelial and low malignant potential ovarian tumours.
Funded Biomarker Disease Site: Ovary
Biomarker: MLH1, MSH2, MSH6, PMS2
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System